Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in HER2-expressing advanced gastric or colorectal cancer
NCT04513223Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and colorectal cancer (CRC), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 21 days and Recommended Phase 2 Dose at 21 days. Started Mar 2021; status: completed.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04513223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513223.